Breaking News

Everest Medicines Invests $30.9M in I-Mab

I-Mab's clinical translational capabilities in the U.S. complement Everest's strong Asia presence.

Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, has made a $30.9 million strategic equity investment in I-Mab.  “This strategic equity investment furthers our plan to be an active player in next-generation oncology programs across global markets. Everest and its Board of Directors believe this investment recognizes I-Mab’s unique clinical translational capabilities in th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters